Ligand Pharmaceuticals Incorporated (LGND)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| DSO | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
Based on the provided data, the days of sales outstanding (DSO) for Ligand Pharmaceuticals Incorporated are not available for the specified periods from March 31, 2020, to December 31, 2024. This lack of information on DSO makes it challenging to assess the company's efficiency in collecting accounts receivable and managing its working capital effectively.
Typically, a low DSO indicates that the company is efficient in collecting payments from its customers, which is favorable as it implies better cash flow management. On the other hand, a high DSO may suggest potential issues with the company's credit policies or difficulties in customer collections.
Without specific DSO figures, it is not possible to evaluate the trend over time or make comparisons with industry averages or competitors. It is important for investors and analysts to monitor DSO along with other financial ratios to gain a comprehensive understanding of Ligand Pharmaceuticals' financial performance and liquidity management.
Peer comparison
Dec 31, 2024